Table 3.

Drug‐related adverse events (n/%)

	All			Grade 3–4
Adverse event	Endostar + pemetrexed/cisplatin (n = 56)	Pemetrexed/cisplatin (n = 39)	P	Endostar + pemetrexed/cisplatin (n = 56)	Pemetrexed/cisplatin (n = 39)	P
Any	54 (96.4)	39 (100.0)	0.511	11 (19.6)	9 (23.1)	0.686
Hematological toxicity
Myelosuppression	48 (85.7)	37 (94.9)	0.275	9 (16.1)	6 (15.4)	1.000
Thrombocytopenia	8 (14.3)	3 (7.7)	0.508	2 (3.6)	0 (0.0)	0.511
Hemoglobin reduction	24 (42.9)	20 (51.3)	0.418	1 (1.8)	2 (5.1)	0.749
Non‐hematological toxicity
Increased transaminase	13 (23.2)	9 (23.1)	0.988	—	—	—
Cardiotoxicity	1 (1.8)	1 (2.6)	1.000	1 (1.8)	0 (0.0)	1.000
Renal dysfunction	2 (3.6)	4 (10.3)	0.374	—	—	—
Pigmentation	1 (1.8)	0 (0.0)	1.000	—	—	—
Rash	0 (0.0)	1 (2.6)	0.411	—	—	—
Nausea	50 (89.3)	30 (76.9)	0.104	2 (3.6)	2 (5.1)	1.000
Vomiting	48 (85.7)	29 (74.4)	0.165	2 (3.6)	2 (5.1)	1.000
Fatigue	3 (5.4)	1 (2.6)	0.883	—	—	—
Neurotoxicity	0 (0.0)	1 (2.6)	0.411	—	—	—